HUS Medical Imaging Center, Helsinki University Central Hospital, Helsinki, Finland
- Research Interests
Kim Bergström is a Chief Radiochemist at HUS Medical Imaging Center, Helsinki University Central Hospital. During 2010-2013, he served as Group Leader and Adjunct Professor at the Center for Drug Research, University of Helsinki. In 2007-2010, he served as CEO of Imanext Ltd, a CRO company specializing in molecular imaging. During 2006-2007, he was acting Head of Radiopharmaceutical Research at the University of Helsinki. He worked as R&D Director at MAP Medical Technologies Oy (subsidiary of Schering AG) during 2001-2005, where he earned significant experience in clinical development. Prior to this he served as Vice Chief Chemist at Kuopio University Hospital for more than 10 years, researching and developing molecular imaging tracers and methods. Kim Bergström received his Ph.D. in Radiochemistry in 1995 (University of Kuopio, Finland). Dr. Bergström has obtained international research experience as a post-doctoral fellow (Dept. of Neuropsychiatric Research, Karolinska Hospital, Stockholm) in 1995-1996. He was awarded a degree in Biotechnology Management from the Helsinki School of Business Administration in 2003. Dr. Bergström’s publication list consists of more than 110 peer-reviewed scientific publications in the field of radiochemistry, radiopharmacy and nuclear medicine. Kim Bergström has received the following scientific awards: – Timo Heiskanen Prize, Finnish Society of Nuclear Medicine and Finnish Society of Radiology (2001) – CIS Jean Debiesse Award “Nuclear Medicine”, European Association of Nuclear Medicine (1995) He has served as a member of the editorial boards of Current Radiopharmaceuticals and the European Journal of Nuclear Medicine. He has served as a member of the management boards of three EU COST projects as well as Principal Investigator of a EU EUREKA project and EU IMI project. He has been a reviewer of numerous journals, theses, and licentiate theses, and has been opponent of four theses.